You may be reading this after seeing dramatic headlines, a social post, or a friend's success story and thinking the same thing many patients ask in clinic: “Could Wegovy help me, and is there any reason I shouldn't take it?”

That's the right question.

Wegovy can be an appropriate option for some adults, but it isn't suitable for everyone. The safest starting point isn't enthusiasm about weight loss. It's a careful review of who should not take Wegovy, who may need extra caution, and what a proper UK prescribing assessment should pick up before treatment starts.

If you're trying to sort through mixed messages, the most useful approach is a clinical one. Look past hype, focus on contraindications, and make decisions based on evidence, not momentum.

Table of Contents

• Is Wegovy the Right Choice for Your Weight Loss Journey
  • Start with suitability not popularity
  • What a responsible decision looks like
• Absolute Contraindications The Non-Negotiable Exclusions
  • Thyroid cancer syndromes that rule Wegovy out
  • Pregnancy, trying to conceive, and breastfeeding
• Medical Conditions Requiring Special Caution
  • Eating disorder history needs a better conversation
  • Eye risk in people with unstable diabetic retinopathy
  • Other conditions that need slower specialist review
• Key Clinician Checks Before You Start Wegovy
  • What a proper assessment should include
  • What patients should ask before accepting a prescription
• Warning Signs and Monitoring While on Treatment
  • Symptoms that need prompt review
• Safe and Effective Alternatives If Wegovy Is Not for You
  • Medication is only one route
  • Choosing the right alternative
• Your Next Step A Conversation with Your Clinician

Is Wegovy the Right Choice for Your Weight Loss Journey

Wegovy has become one of the most recognised names in medical weight management in the UK. That visibility can make it seem like the obvious next step when diet efforts have stalled or weight gain has become harder to manage through midlife, after pregnancy, or alongside conditions such as insulin resistance.

But recognition isn't the same as suitability.

A safe decision starts with the less glamorous questions. Your personal medical history. Your family history. Whether you're planning a pregnancy. Whether appetite suppression could interact badly with past disordered eating. Whether another condition changes the balance of benefit and risk.

Start with suitability not popularity

Patients often assume the first question is whether Wegovy works. In practice, the first question is whether it's appropriate for you to take at all. That distinction matters because a medicine can be effective in the right person and still be the wrong choice for someone with a specific contraindication.

If you'd like a plain-English overview of how this class of treatment works before looking at safety in more detail, this guide to GLP-1 medicines and how they're used is a useful starting point.

Clinical reality: Good prescribing is often about ruling a treatment out safely before considering whether it might help.

What a responsible decision looks like

A sensible Wegovy discussion usually includes:

• Medical exclusions: Conditions where treatment shouldn't be prescribed.
• Caution areas: Situations where the answer may be “possibly, but only with closer review”.
• Practical fit: Whether the person can manage side effects, follow-up, monitoring, and treatment goals.
• Alternative options: Other approaches if Wegovy isn't suitable.

That's the lens to use throughout. Not “Can I get it?” but “Should I take it?”

Absolute Contraindications The Non-Negotiable Exclusions

A common UK clinic scenario is the patient who seems like a strong candidate for Wegovy on paper, then one answer changes the whole decision. A parent with medullary thyroid cancer. A positive pregnancy test. A breastfeeding mother hoping to restart weight loss treatment quickly after birth. In these situations, prescribing should stop.

Thyroid cancer syndromes that rule Wegovy out

Wegovy is contraindicated in anyone with a personal history of medullary thyroid carcinoma, a diagnosis of multiple endocrine neoplasia syndrome type 2, or a family history of medullary thyroid carcinoma in a first-degree relative.

The reason is specific. Semaglutide carries a class warning linked to thyroid C-cell tumour findings in animal studies, so clinicians avoid it where the underlying cancer risk is already higher. This is not the same as saying every thyroid problem rules treatment out. An underactive thyroid, past thyroiditis, or routine thyroid blood test abnormalities do not automatically create the same exclusion. The concern is medullary thyroid carcinoma and MEN 2.

That distinction matters because patients are often told they have had "thyroid issues" without being clear what type. Safe prescribing depends on asking the next question and getting the detail right.

For readers wanting broader context on understanding weight loss drug risks, this is a good example of why enthusiasm about weight loss injections should never come before a proper medical history.

Pregnancy, trying to conceive, and breastfeeding

Wegovy should not be used during pregnancy or breastfeeding. It should also be stopped well before a planned pregnancy because semaglutide remains in the body for long enough that a washout period is advised.

In practice, this comes up often in women in their 30s and 40s, including perimenopausal women who may assume fertility is no longer relevant. It can still be relevant. Cycles may be irregular, but pregnancy is still possible, and weight loss treatment should never be started on the assumption that conception cannot happen.

This is one of the clearest examples of clinical trade-offs. A patient may be highly motivated, have obesity-related symptoms, and meet other prescribing criteria. If pregnancy is current, likely, or being actively planned, Wegovy is still the wrong option at that point.

Breastfeeding needs the same caution. There is not enough safety data to treat it as acceptable exposure for an infant.

If you are pregnant, trying for a baby, or breastfeeding, Wegovy is not an appropriate treatment choice right now.

This also needs a careful conversation in patients with a history of eating disorders, especially where pregnancy or the postnatal period has affected weight, appetite, or body image. Appetite suppression can look attractive during a stressful life stage, but the safer course may be to postpone treatment and review the wider clinical picture first.

Medical Conditions Requiring Special Caution

Not everyone falls into a simple yes-or-no category. Some people don't meet an absolute contraindication, but they still need a slower, more careful decision because Wegovy could complicate an existing condition or mask a problem that needs separate treatment.

Eating disorder history needs a better conversation

A frequently overlooked area is eating disorder history. Generic guides usually emphasise thyroid cancer risk and pregnancy, yet many patients ask a more nuanced question: “What if I've had binge eating, purging, or restrictive eating in the past?”

That's a legitimate concern. Clinical guidance discussed in this UK-focused review of what to avoid when taking Wegovy notes that GLP-1 medicines may reduce appetite but don't address the psychological drivers of eating, and some clinicians advise caution or avoidance in active or recent severe eating disorders.

Blanket appetite suppression can work against good care. If the core problem is food preoccupation, rigid control, compensatory behaviours, or distress around eating, medication alone doesn't treat the underlying pattern. In some cases, it may intensify it.

Questions worth raising openly with your clinician include:

• Active symptoms: Ongoing bingeing, purging, restriction, or obsessive calorie control.
• Recent instability: A disorder that's no longer active but still fragile.
• Treatment history: Past therapy, relapse triggers, or current mental health support.
• Motivation: Whether the request is rooted in health goals or in a harmful drive for rapid appetite suppression.

Practical rule: If eating feels chaotic, compulsive, secretive, or punitive, psychological assessment matters as much as weight management assessment.

Eye risk in people with unstable diabetic retinopathy

Another underexplained caution area is unstable diabetic retinopathy. Diabetes UK states that Wegovy may not be suitable for people with unstable diabetic retinopathy because rapid glycaemic improvement can worsen eye conditions, and the same patient-facing guidance notes a lack of UK-specific data on how many perimenopausal women may be excluded or misinformed despite being a group prone to metabolic shifts, as explained in this overview of Wegovy and semaglutide suitability.

This is particularly relevant for perimenopausal women, who are often navigating weight changes, insulin resistance, sleep disruption, and shifting glucose patterns at the same time. Many are searching for help and may not realise that existing eye disease changes the conversation.

The problem isn't that Wegovy is automatically impossible in every woman in perimenopause. It's that eye health can't be ignored if diabetes and retinopathy are already in the picture.

For people also thinking about wider metabolic and cardiovascular considerations in related GLP-1 discussions, this review of cardiac considerations with Ozempic gives useful context, even though any prescribing decision must remain specific to the individual drug and patient.

Other conditions that need slower specialist review

Some additional conditions call for more careful assessment rather than an instant no:

• Previous pancreatitis: Symptoms that mimic or increase concern around pancreatic irritation need proper review before prescribing.
• Significant kidney or liver disease: Vomiting, dehydration, and altered drug tolerance can carry more risk.
• Severe gastrointestinal problems: Delayed gastric emptying and ongoing digestive symptoms may make treatment harder to tolerate.
• Mental health instability: Depression, anxiety, or low mood don't automatically exclude treatment, but major instability means the wider care plan matters.

In these cases, the safest answer is often to pause, gather more history, and decide carefully rather than forcing a quick prescription.

Key Clinician Checks Before You Start Wegovy

A good Wegovy consultation shouldn't feel like an online checkout. It should feel like clinical screening.

What a proper assessment should include

Before any prescription is considered, the clinician should build a full picture of risk, not just confirm that you want help with weight loss.

A sensible pre-treatment review usually covers:

1. Personal medical history
   This includes past pancreatitis, gallbladder problems, diabetes complications, gastrointestinal symptoms, and mental health history.
2. Family history
   For family history, MTC and MEN 2 screening matters. A rushed form with vague tick boxes isn't enough.
3. Current medicines
   Prescribers need to know what else you take, including diabetes treatment, contraception, and medicines that can worsen dehydration or nausea.
4. Pregnancy status and plans
   This should be asked directly, not assumed.
5. Weight history and goals
   The clinician should explore what has and hasn't worked, and whether your expectations are realistic.
6. Ability to manage follow-up
   Side effects, dose escalation, food intake, hydration, and review points all need monitoring.

A practical walkthrough of how regulated access works can help patients spot the difference between real assessment and superficial prescribing. This guide on how to get Wegovy in the UK is useful for that.

For people who like structured self-tracking between appointments, tools such as Cardiogram can also support broader health awareness, though they never replace a clinician's assessment or prescribing review.

Later in the process, many patients find it helpful to hear a clinician explain screening and treatment expectations verbally:

What patients should ask before accepting a prescription

If you're unsure whether the consultation has been thorough enough, ask direct questions:

• Why am I suitable for this medication?
• What in my history would make you say no?
• What side effects should trigger contact or stopping treatment?
• What happens if I'm planning pregnancy or my health changes?
• How will progress and safety be reviewed?

The quality of the screening often tells you as much as the answer itself.

Warning Signs and Monitoring While on Treatment

A common pattern in clinic is this. Someone starts Wegovy, feels sick after the first few doses, assumes that means the medicine is “working”, and keeps escalating despite struggling to eat or drink properly. That is when a manageable side effect can turn into a safety problem.

Early gastrointestinal symptoms are common with semaglutide. Nausea, reduced appetite, reflux, constipation, diarrhoea, and a feeling of fullness can settle as the body adjusts. In practice, I look at impact rather than the label of the symptom. Mild nausea is different from vomiting that stops you keeping fluids down. A smaller appetite is different from barely eating for days, especially in patients already at risk of low protein intake, gallstones, frailty, or disordered eating.

This matters for groups often missed in generic guidance. Perimenopausal women may already be dealing with poor sleep, fatigue, dizziness, palpitations, or irregular eating patterns, so dehydration or under-fuelling can be misread as “hormones” rather than a medication problem. People with a history of binge eating, restrictive dieting, or purging need closer review because appetite suppression can sometimes reinforce unhealthy patterns rather than support stable weight loss.

Symptoms that need prompt review

Contact your prescriber urgently, or seek same-day medical advice, if you develop:

• Severe or persistent abdominal pain: especially pain that is increasing, localised, or associated with vomiting
• Repeated vomiting or inability to keep fluids down: dehydration can develop quickly
• Marked dizziness, fainting, or severe weakness: this needs assessment, not guesswork
• Signs of an allergic reaction: such as swelling, wheeze, widespread rash, or breathing difficulty
• Possible pregnancy: treatment should be reviewed promptly
• New visual symptoms in someone with diabetes: blurred vision or sudden changes should be taken seriously, particularly with known diabetic retinopathy

Do not keep injecting while hoping severe symptoms will pass.

Pregnancy planning also needs active monitoring during treatment. Wegovy should not be used in pregnancy or while breastfeeding, and it needs to be stopped at least two months before a planned pregnancy. That point is easy to miss once weight loss is underway, particularly if cycles become less predictable after weight change or in perimenopause.

Monitoring is not only about spotting emergencies. It is also about checking whether treatment is still appropriate at each dose step. Review hydration, bowel habit, food intake, protein intake, alcohol use, and whether dose increases are being tolerated. If nausea is constant, meals are becoming very restricted, or food-related anxiety is rising, the answer may be to hold the dose, reduce it, or stop. Pressing on is not good medicine.

For some patients, a different treatment is safer or easier to sustain. If tolerability becomes the main barrier, a clinician may discuss whether Orlistat is a more suitable weight-loss medication based on your medical history and risk profile.

Safe and Effective Alternatives If Wegovy Is Not for You

Being told you shouldn't take Wegovy can feel disappointing, especially if you've pinned a lot of hope on it. Clinically, though, ruling out the wrong treatment is progress. It protects you from preventable harm and opens the door to options that fit better.

Medication is only one route

A few alternatives may be considered, depending on your medical profile and treatment goals:

• Structured lifestyle programmes: These work best when they are specific, supported, and realistic. Vague advice to “eat less and move more” rarely helps on its own.
• Other prescription options: For some adults, medicines such as Orlistat may be more appropriate than a GLP-1 medicine. This guide to Orlistat for weight loss explains where it may fit.
• Bariatric surgery pathways: In carefully selected patients, surgery may offer the most suitable long-term option.
• Behavioural or psychological support: This is especially important where emotional eating, binge patterns, trauma, or rigid dieting cycles are driving weight change.

Choosing the right alternative

The best alternative depends on why Wegovy is unsuitable.

If pregnancy is planned, the immediate focus may shift to nutrition, metabolic health, and pre-conception planning. If there's an eating disorder history, therapy and specialist support may matter more than appetite suppression. If retinopathy or another diabetes complication is present, coordination with the wider diabetes team becomes more important than speed.

A practical way to compare options is to ask:

No single route fits every patient. The right plan is the one that is safe enough to continue and realistic enough to maintain.

Your Next Step A Conversation with Your Clinician

If you've been trying to work out who should not take Wegovy, the key message is simple. Suitability depends on more than weight alone.

Some exclusions are firm. A personal or family history of MTC, MEN 2, pregnancy, planned conception within the required washout period, and breastfeeding all need careful attention, with some making treatment clearly inappropriate. Other situations sit in a grey zone but still deserve serious respect, especially eating disorder history, unstable diabetic retinopathy, significant gastrointestinal symptoms, and complex mental or physical health backgrounds.

Bring the full picture to your appointment. Not just your weight, but your family history, medications, reproductive plans, previous side effects from treatments, mental health, and any concern you've been tempted to minimise.

A productive consultation usually includes these questions:

• Am I medically suitable for Wegovy at all?
• Is there anything in my family history that changes the answer?
• Do any of my current conditions require caution or another option?
• What should I monitor if I start?
• What is the best alternative if Wegovy isn't right for me?

Good weight management care isn't about getting to a prescription as fast as possible. It's about reaching a treatment plan you can use safely, with proper supervision and without overlooking risks that matter.

If you want a regulated UK service that puts screening and ongoing support first, Trim offers clinician-led weight management with medically supervised options, careful suitability checks, and continued support if treatment is appropriate for you.